TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Nursing home operators say GLP-1 medications are increasingly common among new residents, including for conditions beyond diabetes and weight management. Facilities are adapting clinical monitoring, while Medicare coverage remains limited: a bridge program runs through 2027, but a more permanent option has been delayed.
GLP-1 medications are showing up more often among nursing home admissions, prompting operators to expand clinical monitoring and confront questions about who pays for costly prescriptions. Lisa Chubb, chief nursing officer for Venza Care, said about 30% to 40% of its new admissions are taking a GLP-1, while coverage rules and the health risks of weight loss for frail residents complicate their use.
Chubb told Skilled Nursing News that the medications were initially associated at her facilities with diabetes and weight loss, but are now being used for a wider range of concerns, including cardiovascular health, metabolic conditions and organ health. She said the share is higher at facilities with more short-stay residents. The report does not provide a national estimate of nursing home use.
Venza has added GLP-1 review to its clinical routines. Chubb said interdisciplinary teams hold weekly “nutrition at risk” meetings, use electronic health record assessments to document medication review and education, and monitor residents’ weight. Registered dietitians also take part in care for residents using the drugs.
Jody O’Mara, chief nursing officer for Journey Skilled Nursing, said the medications could affect facility assessments, admission decisions and quality assurance programs. She also described high-cost drugs as an operational issue, particularly where a pharmacy arrangement makes medication expenses a facility responsibility. Her view that benefits can outweigh costs is an operator’s assessment, not a finding about outcomes across nursing homes.
Care Plans Meet Medication Costs
More residents arriving on GLP-1s could require nursing homes to coordinate medication management with nutrition, hydration and functional status, rather than treating weight change as a straightforward benefit. The stakes are particularly relevant for older adults who may already have frailty, chronic conditions or difficulty maintaining adequate nutrition.
Costs can also shape which prescriptions a facility can support and what residents can afford. A coverage route that lowers a bill but leaves a monthly charge does not eliminate the financial barrier, particularly for residents with limited income. The report does not establish how often cost leads to a prescription being changed or stopped, but it describes reimbursement as a significant consideration for providers.
Products Worth Considering
Levoit Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft²
PHILIPS Hue Smart LED Candle Light Bulb, B39, E12, 2-Pack
Philips Hue Essential Starter Kit with Bridge and 4 E26 Smart Bulbs
As an affiliate, we earn on qualifying purchases.
Medicare Coverage Has Gaps
According to Jessie McGill, a senior curriculum development specialist at the American Association for Post-Acute Care Nursing, a Medicare Part D bridge program covers certain GLP-1 prescriptions for weight loss when the resident has not already been prescribed the drug for diabetes. Eligible drugs named in the report are Wegovy, Zepbound and Foundeo. The program adds a $50 monthly fee alongside Part D coverage, and eligibility depends on factors including BMI and other chronic conditions.
McGill said the bridge program has been extended through 2027, while a more permanent proposal called BALANCE was delayed without a future implementation date. For residents covered under Medicare Part A during a nursing home stay, McGill said the facility may be responsible for the medication cost. She said drugs outside the bridge program can create a substantial expense for operators.
McGill identified expanding Medicare consolidated billing to cover high-cost medications such as GLP-1s as a possible policy change, but said that would require congressional action. The source report does not say such a change has been approved.
“We see a lot of our new admissions coming in with GLP-1s.”
— Lisa Chubb, chief nursing officer for Venza Care
Use, Outcomes and Coverage Questions
The report gives an operator-specific figure from Venza Care, not a national measure of nursing home use. It also does not quantify how GLP-1 treatment affects residents’ health outcomes, staffing needs or facility spending across the sector. Clinicians described potential benefits, but those expectations should not be read as proof of improved outcomes for every resident.
Individual suitability remains a concern. Lauren Stenson of AAPACN said nursing home residents may have frailty, multiple chronic conditions, nutritional concerns and functional limitations; she also identified nausea, vomiting, constipation and dehydration as potential adverse effects. The report does not specify how frequently these effects occur among nursing home residents. The future of BALANCE coverage is also unresolved, and the bridge program’s extension does not settle longer-term payment policy.
Facilities Prepare for Continued Use
With the bridge program extended through 2027, facilities will need to manage current coverage rules while monitoring whether Medicare establishes a permanent option. The report gives no implementation date for BALANCE. McGill said expanding consolidated billing would require congressional action, so any change on that front depends on future policy decisions.
At the facility level, the practices described by Venza point to continued medication review, resident education and monitoring of weight and nutrition. Operators will also have to account for possible medication costs when residents enter a facility. The source does not identify a single standard approach across nursing homes, leaving the balance between resident preferences, clinical risks and payment capacity to be worked through in individual care planning.
Key Questions
How common are GLP-1 medications in nursing homes?
Venza Care’s chief nursing officer said about 30% to 40% of the operator’s new admissions are taking a GLP-1, with a higher share at facilities with more short-stay residents. The report does not provide a national rate.
Which GLP-1 drugs are included in the Medicare bridge program?
The report names Wegovy, Zepbound and Foundeo as eligible drugs under the bridge program. Coverage applies to certain weight-loss prescriptions subject to eligibility requirements; the source does not describe it as general coverage for all GLP-1 use.
How much does the bridge program cost residents?
According to AAPACN’s Jessie McGill, the program adds a $50 monthly fee alongside Part D coverage. She said that can remain difficult for some residents, including people with limited funds.
Why are clinicians cautious about GLP-1s for nursing home residents?
Some residents may already be frail, have multiple chronic conditions or face nutritional and functional challenges. AAPACN’s Lauren Stenson also cited potential adverse effects including nausea, vomiting, constipation and dehydration. The report does not say these risks apply equally to every resident.
When will permanent Medicare coverage be available?
The report says the proposed permanent program, BALANCE, was delayed without a future implementation date. The temporary bridge program has been extended through 2027, but the source does not give a date for a permanent coverage decision.
Source: skillednursingnews.com
